Background. In general there is no evidence of a significant difference between depot and daily GnRH use for pituitary down regulation in IVF cycles using the long protocol, but the data on depot gonadotropin-releasing hormone agonist use in an oocyte donor programs is insufficient. Objectives. To evaluate the results of depot gonadotropin-releasing hormone agonist use (Buserelin depot) in an oocyte donor programs performed for late reproductive age patients and women with diminished ovarian reserve. Method. Retrospective chart review of forty-eight IVF cycles with donor oocytes. Ovulation stimulation protocol with recombinant FSH (rFSH) and GnRH agonist (Buserelin depot), the dose of 225 IU of rFSH has been used. Results. The number of oocytes retrieved were 14.9±6.2, the number of mature oocytes - 12.6 (83.9%), immature oocytes - 2.1 (11.0%), degenerative oocytes per retrieval - 0.7 (3.2%), fertilization rate - 76.6%, blastocyst rate - 45.2%, embryos transferred - 1.6±0.7, pregnancy rate per embryo transfer - 51.4% with 14.3% of multiple gestation, number of embryos appropriate for cryopreservation - 63.2%. Conclusion. Depot gonadotropin-releasing hormone agonist use for an oocyte donor programs showed sufficient pregnancy rate in a group of late reproductive age patients and women with depleted ovarian reserve.